Trial · NCT04316702
Hyperbaric Oxygen Therapy Compared to Pharmaceutical in Fibromyalgia With Emotional Trauma
NCT04316702, Not applicable, Completed, Assaf-Harofeh Medical Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Hyperbaric Oxygen Therapy Compared to Pharmaceutical in Fibromyalgia With Emotional Trauma. Trials, record NCT04316702. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04316702
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hyperbaric Oxygen Therapy Compared to Pharmaceutical in Fibromyalgia With Emotional Trauma
- NCT number
- NCT04316702
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 48 participants, actual
- Lead sponsor
- Assaf-Harofeh Medical Center
- Conditions
- Fibromyalgia, Emotional Trauma
- Interventions
- Hyperbaric oxygen therapy (HBOT) treatment, Cymbalta / Lyrica - Drug treatment
- First posted
- 2020-03-20
- Last updated
- 2026-04-21
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fibromyalgia Impact Questionnaire (FIQ) questionnaire | at 3 months | Fibromyalgia Impact Questionnaire (FIQ) questionnaire score at the end of treatment period (HBOT/pharmaceutical). Score range 0-100, higher score means worse outcome |
| Primary | Fibromyalgia Impact Questionnaire (FIQ) questionnaire | at 6 months | Fibromyalgia Impact Questionnaire (FIQ) questionnaire score at the end of follow up period (HBOT/pharmaceutical). Score range 0-100, higher score means worse outcome |
| Secondary | Widespread pain index questionnaire | at baseline, 3 months, 6 months | Fibromyalgia syndrome symptoms questionnaire named:Wide Spread Pain Index (scale 0-19, higher score means worse outcome) |
| Secondary | Symptoms severity scale questionnaire | at baseline, 3 months, 6 months | Fibromyalgia syndrome symptoms questionnaire named:Symptom Severity Scale (SSS) (scale 0-12, higher score means worse outcome) |
| Secondary | Post traumatic stress disorder (PTSD) symptoms scale (PSS) questionnaire | at baseline, 3 months, 6 months | a 17-item semi-structured interview that assesses the presence and severity of Diagnostic and Statistical Manual (DSM-IV) PTSD symptoms related to a single identified traumatic event in individuals with a known trauma history. scale 0-51, higher score means worse outcome |
| Secondary | Medical somatic dissociation questionnaire (MSDQ) | at baseline, 3 months, 6 months | assess somatic dissociation in the healthcare system setting, Scale 5-130, higher score means worse outcome |
| Secondary | Recovery promoting relationships scale (RPRS) | at baseline, 3 months, 6 months | assesses patient-therapist relationships from the patient's perspective. |
| Secondary | the brief symptom inventory (BSI-18) | at baseline, 3 months, 6 months | evaluate psychological distress, three sub-scales: depression, anxiety, and somatization. scale of 0-24, higher score means worse outcome. |
| Secondary | Beck depression inventory (BDI) | at baseline, 3 months, 6 months | a 21-question multiple choice self-report inventory, designed to measure severity of depression. scale of 0-63, higher score means worse outcome |
| Secondary | Short form health survey (sf-36) | at baseline, 3 months, 6 months | Quality of life questionnaire, scale of 0-100, higher score means better outcome |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Emoji Emotion Recognition | Secondary outcome |
Source ConductCognition
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04316702
GET https://conductscience.org/api/trials/v1/NCT04316702/registered?page=2